目的:研究多肽药物汇利心康(HLXK)对慢性心衰模型大鼠心肌细胞凋亡的影响。方法:取大鼠随机分为正常对照组、模型组、阳性对照(灌胃氯沙坦钾6mg·kg-1,每日1次)组和HLXK低、中、高剂量(腹腔注射10、30、90μg·kg-1,每日2次)组,每组8只,后5组腹腔注射盐酸多柔比星(隔天给药,15d)建立慢性心衰模型,同时给予相应药物。10周后用高频彩超测定各组大鼠左心室收缩末期容积(LVESV)和射血分数(EF),免疫组化法检测心肌组织中Bcl-2、Bax蛋白表达。结果:与正常对照组比较,模型组大鼠LVESV明显增加,EF明显减少(P〈0·01),表明其心功能明显减退;且Bcl-2蛋白表达明显减弱,Bax蛋白表达明显增强(P〈0·01)。与模型组比较,阳性对照组和HLXK中、高剂量组LVESV明显减少,EF明显增加,Bax蛋白表达明显减弱,Bcl-2蛋白表达明显增强(P〈0·05或P〈0·01);HLXK低剂量组仅Bax蛋白表达明显减弱,Bcl-2蛋白表达明显增强(P〈0·05)。结论:HLXK可能通过增强模型大鼠Bcl-2蛋白表达、抑制Bax蛋白表达,从而抑制心肌细胞凋亡。
OBJECTIVE:To explore the effects of the polypeptide drug Huilixinkang(HLXK) on the myocardial apoptosis in rats with chronic heart failure(CHF).METHODS:Rats were randomly divided into normal control group,model group,positive control group(intragastric administration of losartan 6 mg·kg-1,once a day) and HLXK low-dose,medium-dose and high-dose groups(intraperitoneal injection 10,30,90 μg·kg-1,twice a day) with 8 rats in each group.The latter 5 groups were given intraperitoneal injection of doxorubicin hydrochloride every 2 days for consecutive 15 days to establish CHF model and received relevant medicine.After 10 weeks of treatment,LVESV and EF of rats were measured by echocardiography,and expression of Bcl-2 and Bax in myocardial tissue were determined with immunohistochemistry technique.RESULTS:Compared with normal control group,LVESV of model group increased significantly,and EF decreased significantly(P〈0.01),the heart function markedly reduced and the expression of Bcl-2 protein decreased and expression of Bax protein enhanced significantly(P〈0.01).Compared with model group,LVESV level and expression of Bax protein in positive control group and HLXK medium-dose and high-dose groups decreased significantly while EF level and expression of Bcl-2 protein increased significantly(P〈0.05 or P〈0.01).The expression of Bax protein in HLXK low-dose group decreased significantly,and the expression of Bcl-2 protein enhanced significantly(P〈0.05).CONCLUSION:HLXK can inhibit myocardial apoptosis by enhancing the protein expression of Bcl-2 and inhibiting the protein expression of Bax.